New device aims to zap diabetic nerve pain

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 19 years or older. * Diagnosis of diabetic peripheral neuropathy (DPN) confirmed by nerve conduction study (EMG/NCS) or skin biopsy. * Persistent neuropathic pain in the lower extremities for ≥6 months. * Average baseline pain score of ≥6 on the Visual Analog Scale (VAS). * DN4 score ≥4, indicating neuropathic pain characteristics. * Inadequate pain relief with conventional medical therapy, including at least two classes of analgesic or neuropathic pain medications (e.g., gabapentinoids, SNRIs, TCAs, opioids). * Candidate for spinal cord stimulation based on clinical evaluation by the treating physician. * Able and willing to comply with all trial procedures and follow-up visits. * Able to provide written informed consent in English or in an IRB-approved translated language. Exclusion Criteria: * Prior spinal cord stimulator implantation or previous SCS trial that was unsuccessful. * Contraindications to SCS placement, including: * Active systemic infection or local infection at planned needle entry site * Bleeding disorders or inability to temporarily discontinue anticoagulation if required * Known allergy to device materials or components * Severe uncontrolled medical conditions that increase surgical risk, including: * Unstable cardiovascular disease * Severe renal or hepatic dysfunction * Uncontrolled diabetes (e.g., HbA1c \> 10%) * Severe or uncontrolled psychiatric illness that, in the investigator's judgment, may interfere with study compliance. * Current substance use disorder, including active opioid misuse or illicit drug use, based on clinician assessment. * Pregnancy or planning to become pregnant during the study period. * Life expectancy less than 12 months. * Participation in another interventional clinical trial that may confound results or interfere with study procedures. * Any condition that, in the investigator's opinion, makes the participant unsuitable for SCS therapy or the study.